More about

Ovarian Cancer

News
October 20, 2020
2 min read
Save

Incomplete pregnancies linked to reduced risk for ovarian cancer

Incomplete pregnancies linked to reduced risk for ovarian cancer

Incomplete pregnancies appeared associated with reduced risk for invasive epithelial ovarian cancer, according to results of a study published in Journal of the National Cancer Institute.

News
October 13, 2020
2 min read
Save

No survival benefit with nivolumab vs. chemotherapy in platinum-resistant ovarian cancer

Nivolumab did not improve overall survival compared with gemcitabine or pegylated liposomal doxorubicin in platinum-resistant ovarian cancer; however, it was better tolerated, according to results presented at ESMO Virtual Congress 2020.

News
October 11, 2020
2 min read
Save

Chemosensitivity may predict PFS after first-line treatment in ovarian cancer

KELIM, a model-based parameter from CA-125 kinetics, was an independent prognostic factor of progression-free survival for 5 years after first-line treatment in patients with ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

News
October 10, 2020
2 min read
Save

Triple therapy shows promise in non-germline BRCA-mutated ovarian cancer

Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.

News
October 09, 2020
2 min read
Save

Olaparib plus bevacizumab benefits beyond first progression in high‐grade ovarian carcinoma

Adding maintenance olaparib to bevacizumab provided a benefit beyond first progression, with a substantial second progression-free survival benefit, in patients with newly diagnosed, advanced high-grade ovarian carcinoma, according to data presented at ESMO Virtual Congress 2020.

News
October 07, 2020
1 min read
Save

Quality of life comparable between niraparib, placebo in advanced ovarian cancer

Quality of life comparable between niraparib, placebo in advanced ovarian cancer

Patients with gynecologic cancers that responded to first-line platinum-based chemotherapy receiving niraparib did not show lower health-related quality of life compared with placebo, according to data presented at ESMO Virtual Congress 2020.

News
October 06, 2020
1 min read
Save

Veliparib plus chemotherapy, chemo alone improve QOL in advanced-stage ovarian cancer

Veliparib plus carboplatin/paclitaxel followed by veliparib maintenance showed smaller improvements in health-related quality of life measures from baseline compared with carboplatin/paclitaxel alone among patients with newly diagnosed stage III or IV ovarian cancer.

News
October 05, 2020
1 min read
Save

Subsequent chemotherapy less effective in recurrent ovarian cancer, maintenance olaparib

Subsequent chemotherapy showed less efficacy in BRCA 1 and 2-mutated, platinum-sensitive, recurrent epithelial ovarian cancer treated with maintenance olaparib compared with placebo, according to a presentation at ESMO Virtual Congress 2020.

News
October 05, 2020
1 min read
Save

Pazopanib, paclitaxel nonsuperior to paclitaxel during recurrent ovarian cancer maintenance

Adding pazopanib to paclitaxel in patients with recurrent ovarian cancer progressing during bevacizumab maintenance therapy was not superior to paclitaxel alone, according to data presented at ESMO Virtual Congress 2020.

News
September 30, 2020
1 min read
Save

Nine important updates for Gynecologic Cancer Awareness Month

Nine important updates for Gynecologic Cancer Awareness Month

September is Gynecologic Cancer Awareness Month, an awareness campaign launched in 1999 by Foundation for Women’s Cancer.

View more